在血管瘤中使用普罗兰诺洛单一疗法 - 一个机会窗口研究 (PropAngio)
Alaa Embaby1, Kimberley M Heinhuis1, Nikki S IJzerman2
1Department of Medical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, Netherlands; Department of Clinical Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, Netherlands.
European journal of cancer (Oxford, England : 1990)
|March 7, 2024
概括
在血管肉瘤患者中,普罗普拉诺洛单一治疗显示出有限的临床疗效. 虽然两名患者经历了临床益处,但需要进一步的研究来探索这种罕见癌症的有效治疗方法.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 血管肉瘤是一种罕见的,侵略性的内皮细胞癌.
- 作为β-阻断剂的普罗普拉诺洛尔在临床前血管肉瘤模型中表现出抗瘤活性.
- 之前的病例报告表明,propranolol在治疗血管肉瘤方面具有潜力.
研究的目的:
- 为了前性地评估propranolol作为血管肉瘤单一治疗的抗瘤活性.
- 在开始标准治疗之前评估临床和探索性终点.
主要方法:
- 14名血管肉瘤患者接受了普拉诺洛尔 (80-240毫克/天) 3-6周.
- 主要终点:临床反应 (RECIST 1.1或皮肤改善的稳定疾病).
- 探索性终点包括组织学反应 (Ki-67),PET反应和β受体表达.
主要成果:
- 14名患者中有2名 (14%) 实现了临床反应;一个人在PET-CT上有部分代谢反应.
- 没有观察到组织学反应.
- 最常见的不良事件是1/2级胸 (86%);没有严重的不良事件发生.
- 在大多数瘤中,ADRB2过度表达;ADRB1没有过度表达.
结论:
- 在这个机会窗口的试验中,普罗普拉诺洛尔单一治疗没有显示出显著的临床疗效.
- 两名患者经历了临床益处,这表明了潜在的响应者的子集.
- 在本研究中,ADRB1/2表达与临床反应没有相关性.
相关概念视频
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
801
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
801
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
429
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
181
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
181
01:22Heart Failure Drugs: β-Blockers
338
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
338
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
512
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
512
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
447
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
447